These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18004211)

  • 1. Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar.
    Spraggs C; McCarthy A; McCarthy L; Hong G; Hughes A; Lin X; Sathe G; Smart D; Traini C; Van Horn S; Warren L; Mosteller M
    Pharmacogenet Genomics; 2007 Dec; 17(12):1065-76. PubMed ID: 18004211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
    Geese WJ; Achanzar W; Rubin C; Hariharan N; Cheng P; Tomlinson L; Ordway N; Dracopoli NC; Delmonte T; Hui L; Krishnan B; Cosma G; Ranade K
    Pharmacogenet Genomics; 2008 Oct; 18(10):903-10. PubMed ID: 18794727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats.
    Chen L; Yang B; McNulty JA; Clifton LG; Binz JG; Grimes AM; Strum JC; Harrington WW; Chen Z; Balon TW; Stimpson SA; Brown KK
    J Pharmacol Exp Ther; 2005 Feb; 312(2):718-25. PubMed ID: 15475592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.
    McHutchison J; Goodman Z; Patel K; Makhlouf H; Rodriguez-Torres M; Shiffman M; Rockey D; Husa P; Chuang WL; Levine R; Jonas M; Theodore D; Brigandi R; Webster A; Schultz M; Watson H; Stancil B; Gardner S;
    Gastroenterology; 2010 Apr; 138(4):1365-73, 1373.e1-2. PubMed ID: 20004661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a single nucleotide polymorphism showing no insulin-mediated suppression of the promoter activity in the human insulin receptor substrate 2 gene.
    Iwamoto K; Mori H; Okazawa H; Hashiramoto M; Kasuga M
    Diabetologia; 2002 Aug; 45(8):1182-95. PubMed ID: 12189449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.
    Hansen L; Ekstrøm CT; Tabanera Y Palacios R; Anant M; Wassermann K; Reinhardt RR
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3446-50. PubMed ID: 16822823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic variations and transcriptional regulation of the human mu-opioid receptor gene.
    Bayerer B; Stamer U; Hoeft A; Stüber F
    Eur J Pain; 2007 May; 11(4):421-7. PubMed ID: 16843022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel variants in the putative peroxisome proliferator-activated receptor {gamma} promoter and relationships with obesity in men.
    Larsen TM; Larsen LH; Torekov SK; Ek J; Black E; Toubro S; Astrup A; Sørensen TI; Hansen T; Pedersen O
    Obes Res; 2005 Jun; 13(6):953-8. PubMed ID: 15976135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk.
    Tönjes A; Stumvoll M
    Curr Opin Clin Nutr Metab Care; 2007 Jul; 10(4):410-4. PubMed ID: 17563457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INT-131, a PPARgamma agonist for the treatment of type 2 diabetes.
    Kintscher U; Goebel M
    Curr Opin Investig Drugs; 2009 Apr; 10(4):381-7. PubMed ID: 19337960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of genetic variation of PPARgamma in humans.
    Meirhaeghe A; Amouyel P
    Mol Genet Metab; 2004; 83(1-2):93-102. PubMed ID: 15464424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma (PPAR) agonism reduces the insulin-stimulated increase in circulating interleukin-6 in GH replaced GH-deficient adults.
    Krag MB; Rasmussen LM; Hansen TK; Frystyk J; Flyvbjerg A; Møller N; Jørgensen JO
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):363-8. PubMed ID: 19067726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo.
    Kumar AP; Quake AL; Chang MK; Zhou T; Lim KS; Singh R; Hewitt RE; Salto-Tellez M; Pervaiz S; Clément MV
    Cancer Res; 2009 Nov; 69(22):8636-44. PubMed ID: 19887620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
    Du J; Zhang L; Liu S; Zhang C; Huang X; Li J; Zhao N; Wang Z
    Biochem Biophys Res Commun; 2009 Jun; 383(4):485-90. PubMed ID: 19383491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of peroxisome proliferator-activated receptors gamma and delta on adiposity in toddlers and preschoolers in the GENESIS Study.
    Lagou V; Scott RA; Manios Y; Chen TL; Wang G; Grammatikaki E; Kortsalioudaki C; Liarigkovinos T; Moschonis G; Roma-Giannikou E; Pitsiladis YP
    Obesity (Silver Spring); 2008 Apr; 16(4):913-8. PubMed ID: 18379566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism of peroxisome proliferator-activated receptor gamma is not associated to Japanese ulcerative colitis.
    Wang F; Tahara T; Arisawa T; Sakata M; Takahama K; Watanabe M; Hirata I; Nakano H
    Hepatogastroenterology; 2008; 55(81):73-5. PubMed ID: 18507082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.